Notification dose intensification biologicals
There has been an important change in the reimbursement from infliximab since the transfer from paper request forms to CIVARS as of 01/03/2022
Overlijdensbericht
Dear colleague,
There has been an important change in the reimbursement from infliximab since the transfer from paper request forms to CIVARS as of 01/03/2022. This change was not communicate to the BIRD by the RIZIV/INAMI or by the registration holders of the originator or biosimilar. From 01/03/2022 it is no longer possible to optimize the interval of infliximab in patients with Crohn’s disease based on reimbursement.
Letter concerning change in reimbursement
Word lid
Elke arts met interesse voor de gastro-enterologie kan het lidmaatschap aanvragen.
